

FOR IMMEDIATE RELEASE

The ETG Companies Acquire Key Gene Technology IP from International Genomics

*Regulatory Single Nucleotide Polymorphism (SNP) Identification and Mapping Patents Will
Help Advance Genetic Screening and Genetic Research*

APRIL 30, 2005 (NEW YORK): The ETG Companies (ETG) announced today their acquisition of intellectual property, including patents and patent applications, from International Genomics relating to Regulatory Single Nucleotide Polymorphisms (SNPs).

“We believe this IP, developed for International Genomics by one of the top researchers in the field, has significant value in the areas of genetic screening and research, particularly when combined with other, complementary patents in the field,” said Alex Evans, ETG President and Chief Operating Officer.

SNPs are telltale variations among people in the expected genetic code stored in their DNA. SNPs which occur within so-called “coding sequences” in DNA are important because they can alter how an organism creates necessary proteins, potentially leading to disease. Isolating and mapping SNPs effectively is an essential part of pinpointing possible genetic predispositions to certain diseases.

The intellectual property from International Genomics includes sets of SNPs and technology for identifying SNPs.

More information may be found about SNPs at
<http://www.ncbi.nlm.nih.gov/About/primer/snps.html>.

About The ETG Companies

The ETG Companies are a diverse family of global businesses and joint ventures in energy, logistics, shipping, financial services, electronics, industrial controls, software and information services, medical devices and biotechnology, data communications, national security, food and beverage, and real estate. Additional information may be found at www.etgglobal.com.

* * * * *

For further information, contact:

Mike Pitonyak
ETG International
+1 212.813.9360
media@etgint.com